Cognitive and psychiatric effects of topiramate monotherapy in migraine treatment: An open study

A. Romigi, A. Cervellino, M. G. Marciani, F. Izzi, R. Massoud, M. Corona, F. Torelli, S. Zannino, E. Uasone, F. Placidi

Research output: Contribution to journalArticlepeer-review


Few data are available on cognitive and psychiatric effects of topiramate (TPM) monotherapy in migraine. Twenty patients affected by migraine were treated with TPM monotherapy. At the same time, twenty control subjects were selected. A comprehensive neuropsychological and behavioural battery of tests were performed at baseline (T0), at titration (T1) and in maintenance period (T2). Topiramate serum levels were also investigated at T1 and T2. On comparison with the control group, no cognitive and psychiatric differences were detected at baseline. A significant reduction of word fluency score (P <0.05) was evident after TPM treatment, both at T1 and T2. No patient developed psychiatric adverse events. TPM induced an impairment of verbal fluency and no psychiatric adverse events, demonstrating selective negative cognitive profile in migraine therapy. Slow titration, low doses, lack of previous psychiatric disorders and/or familial history may explain our data.

Original languageEnglish
Pages (from-to)190-195
Number of pages6
JournalEuropean Journal of Neurology
Issue number2
Publication statusPublished - Feb 2008


  • Cognition
  • Migraine
  • Psychiatric effects
  • Topiramate

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Cognitive and psychiatric effects of topiramate monotherapy in migraine treatment: An open study'. Together they form a unique fingerprint.

Cite this